185 related articles for article (PubMed ID: 10943321)
1. Skin cancer--prospects for novel therapeutic approaches.
Stingl G
Ernst Schering Res Found Workshop; 2000; (30):137-53. PubMed ID: 10943321
[No Abstract] [Full Text] [Related]
2. Cancer immunotherapy. Neo approaches to cancer vaccines.
Delamarre L; Mellman I; Yadav M
Science; 2015 May; 348(6236):760-1. PubMed ID: 25977539
[No Abstract] [Full Text] [Related]
3. [Immunotherapy for melanoma: how can tolerance be overcome?].
Robert C
Ann Dermatol Venereol; 2001; 128(6-7):709-13. PubMed ID: 11460031
[No Abstract] [Full Text] [Related]
4. Melanoma vaccines.
Chapman PB
Semin Oncol; 2007 Dec; 34(6):516-23. PubMed ID: 18083375
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of melanoma.
Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
[TBL] [Abstract][Full Text] [Related]
6. Clinical genetics. Sequencing for tailored melanoma immunotherapy.
Jones B
Nat Rev Genet; 2015 May; 16(5):259. PubMed ID: 26065036
[No Abstract] [Full Text] [Related]
7. Immunotherapy of melanoma.
Smith C; Cerundolo V
Immunology; 2001 Sep; 104(1):1-7. PubMed ID: 11576213
[No Abstract] [Full Text] [Related]
8. Melanoma vaccines.
Perales MA; Wolchok JD
Cancer Invest; 2002; 20(7-8):1012-26. PubMed ID: 12449735
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for advanced melanoma: Current knowledge and future directions.
Nakamura K; Okuyama R
J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
[TBL] [Abstract][Full Text] [Related]
10. Melanoma vaccines: breakthrough or bust?
Sabel MS; Sondak VK
Cancer Invest; 2002; 20(7-8):1114-6. PubMed ID: 12449744
[No Abstract] [Full Text] [Related]
11. Melanoma vaccines: in search of a clinical paradigm.
Storkus WJ
Melanoma Res; 2007 Jun; 17(3):137-8. PubMed ID: 17505258
[No Abstract] [Full Text] [Related]
12. Melanoma immunotherapy: historical precedents, recent successes and future prospects.
Raaijmakers MI; Rozati S; Goldinger SM; Widmer DS; Dummer R; Levesque MP
Immunotherapy; 2013 Feb; 5(2):169-82. PubMed ID: 23413908
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for the development of cancer vaccines: current status.
Copier J; Whelan M; Dalgleish A
Mol Diagn Ther; 2006; 10(6):337-43. PubMed ID: 17154650
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy and experimental approaches for metastatic melanoma.
Atkins MB
Hematol Oncol Clin North Am; 1998 Aug; 12(4):877-902, viii. PubMed ID: 9759585
[TBL] [Abstract][Full Text] [Related]
15. Self-recognition and tumor response to immunotherapy.
Ernstoff MS
J Clin Oncol; 2005 Sep; 23(25):5875-7. PubMed ID: 16087939
[No Abstract] [Full Text] [Related]
16. [Dendritic cells--a new weapon in therapy of melanoma?].
Enk A
Hautarzt; 1996 Jun; 47(6):488-90. PubMed ID: 8778075
[No Abstract] [Full Text] [Related]
17. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
[TBL] [Abstract][Full Text] [Related]
18. [New aspects of immunotherapy of malignant melanoma].
Enk A
Praxis (Bern 1994); 2001 Mar; 90(10):403-6. PubMed ID: 11305186
[TBL] [Abstract][Full Text] [Related]
19. Melanoma vaccines: prim and proper presentation.
Timmerman JM; Levy R
Nat Med; 1998 Mar; 4(3):269-70. PubMed ID: 9500593
[No Abstract] [Full Text] [Related]
20. [Active specific immunotherapy of malignant melanoma].
Lotem M; Shiloni E; Ingber A; Peretz T
Harefuah; 1997 Aug; 133(3-4):122-6. PubMed ID: 9332080
[No Abstract] [Full Text] [Related]
[Next] [New Search]
